Kangxin Pharmaceutical (01681.HK) plans to acquire 30% equity of Shanghai Huamao Pharmaceutical Co., Ltd.

The Zhixin Financial APP reported that Health Essence Pharmaceutical (01681.HK) issued an announcement on June 8, 2026. The company's wholly-owned subsidiary, Guangzhou Health Essence Pharmaceutical Co., Ltd. (Guangzhou Health Essence), entered into an investment agreement with Shanghai Huamao Pharmaceutical Co., Ltd., a limited liability company registered in Shanghai, China (the target company) and its existing shareholders.